Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension.
Arterial hypertension
Calcification
Osteoprotegerin
Selenium
Journal
Cardiovascular toxicology
ISSN: 1559-0259
Titre abrégé: Cardiovasc Toxicol
Pays: United States
ID NLM: 101135818
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
03
02
2022
accepted:
31
03
2022
pubmed:
13
4
2022
medline:
14
6
2022
entrez:
12
4
2022
Statut:
ppublish
Résumé
The aim of the study was to determine the relationship between the serum selenium concentration (Se-S) and the blood concentrations of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-Β ligand (RANKL) and the OPG/RANKL ratio in patients with arterial hypertension. The study group comprised 138 patients with arterial hypertension (age: 56.04 ± 11.59 years). Se-S was determined in all the subjects. Based on the Se-S, the following subgroups were distinguished: a subgroup of patients with a lower Se-S ("low-Se", Se-S < median) and a subgroup of patients with a higher Se-S ("high-Se", Se-S ≥ median). Moreover, the blood concentrations of the parameters of bone metabolism and extraskeletal calcification were assessed: OPG and RANKL. The OPG/RANKL ratio was calculated. In the "low-Se" subgroup, the RANKL concentration was statistically significantly lower, and the OPG/RANKL ratio was statistically significantly higher than in the patients in the "high-Se" subgroup. The correlation analysis showed the negative linear relationships between Se-S and OPG (r = - 0.25, p < 0.05) and between Se-S and OPG/RANKL (r = - 0.47, p < 0.05). Moreover, Se-S positively correlated with RANKL (r = 0.33, p < 0.05). In regression analysis, higher body mass index (BMI), smoking and lower Se-S were independently associated with a higher OPG/RANKL ratio, while lower BMI, use of diuretics, β-blockers and ACE inhibitors and lower OPG/RANKL ratio with effective blood pressure control. In summary, in the group of patients with arterial hypertension, lower Se-S is associated with an unfavourable prognostic panel of parameters of bone metabolism and extraskeletal calcification. Lower Se-S is an independent risk factor for a higher OPG/RANKL ratio, which is an independent prediction factor of ineffective blood pressure control in patients with hypertension.
Identifiants
pubmed: 35412194
doi: 10.1007/s12012-022-09741-x
pii: 10.1007/s12012-022-09741-x
doi:
Substances chimiques
NF-kappa B
0
Osteoprotegerin
0
RANK Ligand
0
Receptor Activator of Nuclear Factor-kappa B
0
TNFRSF11A protein, human
0
Selenium
H6241UJ22B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
620-630Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
NCD Risk Factor Collaboration (NCD-RisC). (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 398(10304), 957–980. https://doi.org/10.1016/S0140-6736(21)01330-1
doi: 10.1016/S0140-6736(21)01330-1
Nguyen, T. N., & Chow, C. K. (2021). Global and national high blood pressure burden and control. Lancet, 398(10304), 932–933. https://doi.org/10.1016/S0140-6736(21)01688-3
doi: 10.1016/S0140-6736(21)01688-3
pubmed: 34450082
GBD 2019 Risk Factors Collaborators. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396(10258), 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2
doi: 10.1016/S0140-6736(20)30752-2
Nakanishi, R., Baskaran, L., Gransar, H., Budoff, M. J., Achenbach, S., Al-Mallah, M., Cademartiri, F., Callister, T. Q., Chang, H. J., Chinnaiyan, K., Chow, B., DeLago, A., Hadamitzky, M., Hausleiter, J., Cury, R., Feuchtner, G., Kim, Y. J., Leipsic, J., Kaufmann, P. A., Maffei, E., et al. (2017). Relationship of hypertension to coronary atherosclerosis and cardiac events in patients with coronary computed tomographic angiography. Hypertension, 70(2), 293–299. https://doi.org/10.1161/HYPERTENSIONAHA.117.09402
doi: 10.1161/HYPERTENSIONAHA.117.09402
pubmed: 28607128
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., et al. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89(2), 309–319. https://doi.org/10.1016/s0092-8674(00)80209-3
doi: 10.1016/s0092-8674(00)80209-3
pubmed: 9108485
Boyce, B. F., & Xing, L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research and Therapy, 9 Suppl 1(Suppl 1), S1. https://doi.org/10.1186/ar2165
doi: 10.1186/ar2165
pubmed: 17634140
Rochette, L., Meloux, A., Rigal, E., Zeller, M., Cottin, Y., & Vergely, C. (2019). The role of osteoprotegerin and its ligands in vascular function. International Journal of Molecular Sciences, 20(3), 705. https://doi.org/10.3390/ijms20030705
doi: 10.3390/ijms20030705
pmcid: 6387017
Pérez de Ciriza, C., Lawrie, A., & Varo, N. (2015). Osteoprotegerin in cardiometabolic disorders. International Journal of Endocrinology, 2015, 564934. https://doi.org/10.1155/2015/564934
doi: 10.1155/2015/564934
pubmed: 26078757
pmcid: 4442310
Venuraju, S. M., Yerramasu, A., Corder, R., & Lahiri, A. (2010). Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. Journal of the American College of Cardiology, 55(19), 2049–2061. https://doi.org/10.1016/j.jacc.2010.03.013
doi: 10.1016/j.jacc.2010.03.013
pubmed: 20447527
Wu, J., Li, X., Gao, F., Gao, S., Lyu, J., & Qiang, H. (2020). Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis. Bioscience Reports, 40(10), BSR20202156. https://doi.org/10.1042/BSR20202156
doi: 10.1042/BSR20202156
pubmed: 32955093
pmcid: 7536329
Tschiderer, L., Willeit, J., Schett, G., Kiechl, S., & Willeit, P. (2017). Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS ONE, 12(8), e0183910. https://doi.org/10.1371/journal.pone.0183910
doi: 10.1371/journal.pone.0183910
pubmed: 28837646
pmcid: 5570489
Hariharan, S., & Dharmaraj, S. (2020). Selenium and selenoproteins: It’s role in regulation of inflammation. Inflammopharmacology, 28(3), 667–695. https://doi.org/10.1007/s10787-020-00690-x
doi: 10.1007/s10787-020-00690-x
pubmed: 32144521
pmcid: 7222958
Senoner, T., & Dichtl, W. (2019). Oxidative stress in cardiovascular diseases: Still a therapeutic target? Nutrients, 11(9), 2090. https://doi.org/10.3390/nu11092090
doi: 10.3390/nu11092090
pmcid: 6769522
Liu, H., Xu, H., & Huang, K. (2017). Selenium in the prevention of atherosclerosis and its underlying mechanisms. Metallomics, 9(1), 21–37. https://doi.org/10.1039/c6mt00195e
doi: 10.1039/c6mt00195e
pubmed: 28009916
Parati, G., Stergiou, G., O’Brien, E., Asmar, R., Beilin, L., Bilo, G., Clement, D., de la Sierra, A., de Leeuw, P., Dolan, E., Fagard, R., Graves, J., Head, G. A., Imai, Y., Kario, K., Lurbe, E., Mallion, J. M., Mancia, G., Mengden, T., Myers, M., et al. (2014). European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension, 32(7), 1359–1366. https://doi.org/10.1097/HJH.0000000000000221
doi: 10.1097/HJH.0000000000000221
pubmed: 24886823
Stoffaneller, R., & Morse, N. L. (2015). A review of dietary selenium intake and selenium status in Europe and the Middle East. Nutrients, 7(3), 1494–1537. https://doi.org/10.3390/nu7031494
doi: 10.3390/nu7031494
pubmed: 25734564
pmcid: 4377864
Hoeg, A., Gogakos, A., Murphy, E., Mueller, S., Köhrle, J., Reid, D. M., Glüer, C. C., Felsenberg, D., Roux, C., Eastell, R., Schomburg, L., & Williams, G. R. (2012). Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 97(11), 4061–4070. https://doi.org/10.1210/jc.2012-2121
doi: 10.1210/jc.2012-2121
pubmed: 22904175
Akbaraly, T. N., Arnaud, J., Rayman, M. P., Hininger-Favier, I., Roussel, A. M., Berr, C., & Fontbonne, A. (2010). Plasma selenium and risk of dysglycemia in an elderly French population: Results from the prospective Epidemiology of Vascular Ageing Study. Nutrition & Metabolism, 7, 21. https://doi.org/10.1186/1743-7075-7-21
doi: 10.1186/1743-7075-7-21
Galan, P., Viteri, F. E., Bertrais, S., Czernichow, S., Faure, H., Arnaud, J., Ruffieux, D., Chenal, S., Arnault, N., Favier, A., Roussel, A. M., & Hercberg, S. (2005). Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. European journal of clinical nutrition, 59(10), 1181–1190. https://doi.org/10.1038/sj.ejcn.1602230
doi: 10.1038/sj.ejcn.1602230
pubmed: 16034362
González, S., Huerta, J. M., Fernández, S., Patterson, E. M., & Lasheras, C. (2006). Food intake and serum selenium concentration in elderly people. Annals of nutrition & metabolism, 50(2), 126–131. https://doi.org/10.1159/000090633
doi: 10.1159/000090633
Spina, A., Guallar, E., Rayman, M. P., Tigbe, W., Kandala, N. B., & Stranges, S. (2013). Anthropometric indices and selenium status in British adults: The U.K. National Diet and Nutrition Survey. Free Radical Biology & Medicine, 65, 1315–1321. https://doi.org/10.1016/j.freeradbiomed.2013.09.025
doi: 10.1016/j.freeradbiomed.2013.09.025
Rayman, M. P., Blundell-Pound, G., Pastor-Barriuso, R., Guallar, E., Steinbrenner, H., & Stranges, S. (2012). A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS ONE, 7(9), e45269. https://doi.org/10.1371/journal.pone.0045269
doi: 10.1371/journal.pone.0045269
pubmed: 23028897
pmcid: 3446875
Stranges, S., Laclaustra, M., Ji, C., Cappuccio, F. P., Navas-Acien, A., Ordovas, J. M., Rayman, M., & Guallar, E. (2010). Higher selenium status is associated with adverse blood lipid profile in British adults. The Journal of Nutrition, 140(1), 81–87. https://doi.org/10.3945/jn.109.111252
doi: 10.3945/jn.109.111252
pubmed: 19906812
pmcid: 2793123
Duffield, A. J., Thomson, C. D., Hill, K. E., & Williams, S. (1999). An estimation of selenium requirements for New Zealanders. The American Journal of Clinical Nutrition, 70(5), 896–903. https://doi.org/10.1093/ajcn/70.5.896
doi: 10.1093/ajcn/70.5.896
pubmed: 10539752
Alfthan, G., Aro, A., Arvilommi, H., & Huttunen, J. K. (1991). Selenium metabolism and platelet glutathione peroxidase activity in healthy Finnish men: Effects of selenium yeast, selenite, and selenate. The American Journal of Clinical Nutrition, 53(1), 120–125. https://doi.org/10.1093/ajcn/53.1.120
doi: 10.1093/ajcn/53.1.120
pubmed: 1984336
Vinceti, M., Chawla, R., Filippini, T., Dutt, C., Cilloni, S., Loomba, R., Bargellini, A., Orsini, N., Dhillon, K. S., & Whelton, P. (2019). Blood pressure levels and hypertension prevalence in a high selenium environment: Results from a cross-sectional study. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 29(4), 398–408. https://doi.org/10.1016/j.numecd.2019.01.004
doi: 10.1016/j.numecd.2019.01.004
pubmed: 30782506
Grotto, D., Carneiro, M., de Castro, M. M., Garcia, S. C., & Barbosa Junior, F. (2018). Long-term excessive selenium supplementation induces hypertension in rats. Biological Trace Element Research, 182(1), 70–77. https://doi.org/10.1007/s12011-017-1076-1
doi: 10.1007/s12011-017-1076-1
pubmed: 28634813
Hu, X. F., Eccles, K. M., & Chan, H. M. (2017). High selenium exposure lowers the odds ratios for hypertension, stroke, and myocardial infarction associated with mercury exposure among Inuit in Canada. Environment International, 102, 200–206. https://doi.org/10.1016/j.envint.2017.03.002
doi: 10.1016/j.envint.2017.03.002
pubmed: 28279481
Gharipour, M., Sadeghi, M., Behmanesh, M., Salehi, M., Nezafati, P., & Gharpour, A. (2017). Selenium homeostasis and clustering of cardiovascular risk factors: A systematic review. Acta Biomedica, 88(3), 263–270. https://doi.org/10.23750/abm.v88i3.5701
doi: 10.23750/abm.v88i3.5701
pubmed: 29083329
pmcid: 6142834
Huang, Q. X., Li, J. B., Huang, N., Huang, X. W., Li, Y. L., & Huang, F. X. (2020). Elevated osteoprotegerin concentration predicts increased risk of cardiovascular mortality in patients with chronic kidney disease: A systematic review and meta-analysis. Kidney & Blood Pressure Research, 45(4), 565–575. https://doi.org/10.1159/000508978
doi: 10.1159/000508978
Collin-Osdoby, P. (2004). Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circulation Research, 95(11), 1046–1057. https://doi.org/10.1161/01.RES.0000149165.99974.12
doi: 10.1161/01.RES.0000149165.99974.12
pubmed: 15564564
Kaden, J. J., Bickelhaupt, S., Grobholz, R., Haase, K. K., Sarikoç, A., Kiliç, R., Brueckmann, M., Lang, S., Zahn, I., Vahl, C., Hagl, S., Dempfle, C. E., & Borggrefe, M. (2004). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin regulate aortic valve calcification. Journal of Molecular and Cellular Cardiology, 36(1), 57–66. https://doi.org/10.1016/j.yjmcc.2003.09.015
doi: 10.1016/j.yjmcc.2003.09.015
pubmed: 14734048
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., & Simonet, W. S. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes & Development, 12(9), 1260–1268. https://doi.org/10.1101/gad.12.9.1260
doi: 10.1101/gad.12.9.1260
Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006). Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(9), 2117–2124. https://doi.org/10.1161/01.ATV.0000236428.91125.e6
doi: 10.1161/01.ATV.0000236428.91125.e6
pubmed: 16840715
Alehagen, U., Aaseth, J., Alexander, J., Johansson, P., & Larsson, A. (2020). Supplemental selenium and coenzyme Q10 reduce glycation along with cardiovascular mortality in an elderly population with low selenium status—A four-year, prospective, randomised, double-blind placebo-controlled trial. Journal of Trace Elements in Medicine and Biology, 61, 126541. https://doi.org/10.1016/j.jtemb.2020.126541
doi: 10.1016/j.jtemb.2020.126541
pubmed: 32417634
Alehagen, U., Alexander, J., Aaseth, J., & Larsson, A. (2019). Decrease in inflammatory biomarker concentration by intervention with selenium and coenzyme Q10: A subanalysis of osteopontin, osteoprotergerin, TNFr1, TNFr2 and TWEAK. Journal of Inflammation (London, England), 16, 5. https://doi.org/10.1186/s12950-019-0210-6
doi: 10.1186/s12950-019-0210-6
Asanuma, Y., Chung, C. P., Oeser, A., Solus, J. F., Avalos, I., Gebretsadik, T., Shintani, A., Raggi, P., Sokka, T., Pincus, T., & Stein, C. M. (2007). Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis, 195(2), e135–e141. https://doi.org/10.1016/j.atherosclerosis.2007.04.049
doi: 10.1016/j.atherosclerosis.2007.04.049
pubmed: 17570371
pmcid: 2174431
Shao, J. S., Cheng, S. L., Sadhu, J., & Towler, D. A. (2010). Inflammation and the osteogenic regulation of vascular calcification: A review and perspective. Hypertension, 55(3), 579–592. https://doi.org/10.1161/HYPERTENSIONAHA.109.134205
doi: 10.1161/HYPERTENSIONAHA.109.134205
pubmed: 20101002
Schoppet, M., Schaefer, J. R., & Hofbauer, L. C. (2003). Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation, 107(11), e76. https://doi.org/10.1161/01.cir.0000060815.25798.02
doi: 10.1161/01.cir.0000060815.25798.02
pubmed: 12654623
Semb, A. G., Ueland, T., Aukrust, P., Wareham, N. J., Luben, R., Gullestad, L., Kastelein, J. J., Khaw, K. T., & Boekholdt, S. M. (2009). Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: A nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 975–980. https://doi.org/10.1161/ATVBAHA.109.184101
doi: 10.1161/ATVBAHA.109.184101
pubmed: 19325145
Mohammadpour, A. H., Shamsara, J., Nazemi, S., Ghadirzadeh, S., Shahsavand, S., & Ramezani, M. (2012). Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: A pilot study. Thrombosis, 2012, 306263. https://doi.org/10.1155/2012/306263
doi: 10.1155/2012/306263
pubmed: 22577539
pmcid: 3329856
Bernardes, M., Vieira, T. S., Martins, M. J., Lucas, R., Costa, L., Pereira, J. G., Ventura, F., & Martins, E. (2017). Myocardial perfusion in rheumatoid arthritis patients: Associations with traditional risk factors and novel biomarkers. BioMed Research International, 2017, 6509754. https://doi.org/10.1155/2017/6509754
doi: 10.1155/2017/6509754
pubmed: 28553649
pmcid: 5434312
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017). Obesity and inflammation: The linking mechanism and the complications. Archives of Medical Science, 13(4), 851–863. https://doi.org/10.5114/aoms.2016.58928
doi: 10.5114/aoms.2016.58928
pubmed: 28721154
Elisia, I., Lam, V., Cho, B., Hay, M., Li, M. Y., Yeung, M., Bu, L., Jia, W., Norton, N., Lam, S., & Krystal, G. (2020). The effect of smoking on chronic inflammation, immune function and blood cell composition. Scientific Reports, 10(1), 19480. https://doi.org/10.1038/s41598-020-76556-7
doi: 10.1038/s41598-020-76556-7
pubmed: 33173057
pmcid: 7655856
Duntas, L. H., & Hubalewska-Dydejczyk, A. (2015). Selenium and inflammation-potential use and future perspectives. US Endocrinology, 11(2), 97–102. https://doi.org/10.17925/use.2015.11.02.97
doi: 10.17925/use.2015.11.02.97
Costa, L. C., Fonseca, M., Pinheiro, A., Aguiar, T., Machado, A. N., Quinelato, V., Bonato, L. L., Aguiar, D. P., Vieira, T., Almeida, F., Lobo, J. C., Jordão, M., Lomardo, P. G., Granjeiro, J. M., & Casado, P. L. (2018). Chronic periodontitis and RANKL/OPG ratio in peri-implant mucosae inflammation. Brazilian Dental Journal, 29(1), 14–22. https://doi.org/10.1590/0103-6440201801241
doi: 10.1590/0103-6440201801241
pubmed: 29267518
Straface, G., Biscetti, F., Pitocco, D., Bertoletti, G., Misuraca, M., Vincenzoni, C., Snider, F., Arena, V., Stigliano, E., Angelini, F., Iuliano, L., Boccia, S., de Waure, C., Giacchi, F., Ghirlanda, G., & Flex, A. (2011). Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke, 42(11), 3022–3028. https://doi.org/10.1161/STROKEAHA.111.619288
doi: 10.1161/STROKEAHA.111.619288
pubmed: 21903966
Duan, P., Wang, Z. M., Liu, J., Wang, L. N., Yang, Z., & Tu, P. (2015). Association of gene polymorphisms in RANKL/RANK/OPG system with hypertension and blood pressure in Chinese women. Journal of Human Hypertension, 29(12), 749–753. https://doi.org/10.1038/jhh.2015.13
doi: 10.1038/jhh.2015.13
pubmed: 25810067
Yang, T., Lee, S. Y., Park, K. C., Park, S. H., Chung, J., & Lee, S. (2022). The effects of selenium on bone health: From element to therapeutics. Molecules, 27(2), 392. https://doi.org/10.3390/molecules27020392
doi: 10.3390/molecules27020392
pubmed: 35056706
pmcid: 8780783